Innovative Medicine

The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities

The dapivirine ring is the first long-acting HIV prevention option designed specifically for women Women bear a disproportionate burden of the global HIV epidemic, especially in sub-Saharan Africa International Partnership for Microbicides developed the dapivirine ring through an exclusive license from the Janssen Pharmaceutical Companies of Johnson & Johnson

Application based on Phase 3 SHINE study results, which investigated the safety and efficacy of all-oral ibrutinib in combination with bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma[1]

Aspen will manufacture and provide the Johnson & Johnson COVID-19 vaccine under its own brand name per the terms of agreement Ensuring equitable, global access to COVID-19 vaccines has been a pillar of Johnson & Johnson’s response since the earliest days of the pandemic The production of COVID-19 vaccines on multiple continents is critical to supporting an equitable response, controlling the pandemic, and improving long-term health security

In the pivotal clinical study, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 78 percent of patients who responded experienced a stringent complete response

Initial results from Phase 3 MAGNITUDE study, to be featured in a late-breaking oral presentation at ASCO GU, highlight subset of patients with mCRPC most likely to benefit from treatment

CABENUVA offers virologically suppressed adults living with HIV an injectable treatment option administered as few as six times a year.

Initial results from Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer featured as an oral presentation New data for ERLEADA® (apalutamide) build on more than a decade of experience in prostate cancer; updated clinical trial information for novel drug delivery system TAR-200 plus cetrelimab in early-stage bladder cancer to be presented

The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked highest among 23 active PsA treatment regimens on skin clearance (PASI 90 response) and showed positive joint efficacy (ACR20), including inhibition of structural damage (vdH-S)